Title: Addressing the analytical rigor of omics measurements for clinical research
Day: Monday Lunchtime
Speakers: Dr. Marten F. Snel, SAHMRI, Head of MS Core Facility
Associate Professor Robert Trengove, Murdoch University, Director Separation Science and Metabolomics Laboratory
Synopsis: The translation of discovery biomarker studies has been plagued with obstacles in the path to clinical utility. Small study sizes, poor experimental reproducibility and inappropriate analytical technique continue to confound the efficient translation from bench to bedside. Waters Corporation continues purposeful innovation in biomedical research with these challenges in mind. SONAR data independent acquisition was developed to improve reproducibility, increase speed of analysis for compatibility with large study cohorts whilst maintaining data quality and quantitative accuracy.
In this lunchtime workshop we will hear from two leading researchers who have been successfully addressing the analytical challenges of protein biomarker discovery in clinical research applications.
Topics: Biomarker Discovery, Translational Research, Reproducibility and accuracy of measurements, SONAR data independent acquisition
Proudly sponsored by Waters
Title: Driving personalized medicine through targeted protein biomarker discovery - taking proteomics beyond mass spectrometry
Day: Tuesday Lunchtime
Speakers: Professor Matthias Uhlén (Royal Institute of Technology, Stockholm). Other speakers to be confirmed.
Synopsis: As proteomics takes an increasingly central role in driving precision medicine forwards, many new technologies are coming through to complement mass spectrometry, and in some cases, broaden the possibilities for protein biomarkers in this area. Olink has developed one such enabling technology for protein biomarker discovery, providing high throughput, sensitive analysis of multiple proteins direct from very small volumes of plasma/serum without the need for further sample preparation. Olink technology has been used widely in both the pharma-biotech and clinical research sectors in Europe and the U.S., generating around 90 million protein measurements from over a million samples, and resulting in over 250 peer-reviewed publications. These studies cover many types of applications, from the search for novel drug targets, to protein profiles for patient stratification and risk assessment, as well as to gain invaluable pathophysiological insights across a broad range of disease areas. As Olink expands into the wider Asia region, we are delighted to arrange this workshop at HUPO 2019 in Australia, and to have the opportunity to present a few examples of the many successful protein biomarker studies that have been carried out to date in both wellness and disease. Please come and join the discussion.
Topics: Professor Uhlén will describe how he has utilized Olink protein analysis in a major longitudinal wellness study.
Proudly sponsored by Olink